top of page

Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration a

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer.


Click on this link for more information.

source: http://www.worldpharmanews.com/novartis/3531-novartis-adds-bispecific-antibodies-to-its-growing-immuno-oncology-portfolio-through-collaboration-and-licensing-agreement-with-xencor

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page